Sex: F
Vaccine: COVID19
Symptoms: Uveitis
Clinical narrative: she has been admitted to the ER multiple times due to severe headaches.; myocarditis; pericarditis; inflammation of the cornea and uvea/ uveitis of the eye; chest pain; immune alterations; but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative.; but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative.; but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative.; corneal inflammation; This is a spontaneous report received from contactable reporter(s) (Physician) from medical information team.  A 14 year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HEADACHE (hospitalization), outcome "unknown", described as "she has been admitted to the ER multiple times due to severe headaches."; MYOCARDITIS (medically significant ), outcome "unknown", described as "myocarditis"; PERICARDITIS (medically significant ), outcome "unknown", described as "pericarditis"; UVEITIS (medically significant ), outcome "unknown", described as "inflammation of the cornea and uvea/ uveitis of the eye"; CHEST PAIN (non-serious), outcome "unknown", described as "chest pain"; IMMUNE SYSTEM DISORDER (non-serious), outcome "unknown", described as "immune alterations"; ANTINUCLEAR ANTIBODY NEGATIVE (non-serious), COMPUTERISED TOMOGRAM ABNORMAL (non-serious), ELECTROCARDIOGRAM AMBULATORY ABNORMAL (non-serious), outcome "unknown" and all described as "but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative."; KERATITIS (non-serious), outcome "unknown", described as "corneal inflammation". The events "she has been admitted to the er multiple times due to severe headaches.", "myocarditis", "pericarditis", "inflammation of the cornea and uvea/ uveitis of the eye", "chest pain", "immune alterations", "but so far the tests (ana, ct angio, holter ekg, etc) have been negative.", "but so far the tests (ana, ct angio, holter ekg, etc) have been negative.", "but so far the tests (ana, ct angio, holter ekg, etc) have been negative." and "corneal inflammation" were evaluated at the physician office visit and emergency room visit. The patient underwent the following laboratory tests and procedures: investigation: negative, notes: The probable diagnoses have been immune alterations, myocarditis, and pericarditis, but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative; negative, notes: The probable diagnoses have been immune alterations, myocarditis, and pericarditis, but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative; negative, notes: The probable diagnoses have been immune alterations, myocarditis, and pericarditis, but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative; negative, notes: The probable diagnoses have been immune alterations, myocarditis, and pericarditis, but so far the tests (ANA, CT angio, Holter EKG, etc) have been negative.  Clinical course: The reporter stated that The patient has been visiting several specialist on the last two months, including immunologists, cardiologists, and pediatric cardiologists. Reporter states that there's been a multi-systemic involvement and would like to know how to handle this situation. Reporter wants correlation details. Reporter said that it was just one symptom he was not worried but now the symptoms are increasing.  Reporter does not have all the vaccine information for of patient   The lot number for bnt162b2 was not provided and will be requested during follow up.; Sender's Comments: Based on the current limited available information and the drug-event temporal association, a possible contributory role of the suspect product BNT162B2 to the development of events headache, myocarditis, pericarditis and uveitis cannot be excluded.   The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.